LTRN · NASDAQ · Biotechnology

Lantern Pharma (LTRN)

Develops oncology candidates using data science and biomarker-guided drug development.

$1.94
Pre-market+0.01 (+0.52%)
At close$1.93(−4.46%)

Something off on this page? Send us feedback.

Next report
Nov 11, 2026
in 69 days
EPS estimate
−$0.35
Revenue estimate
Fiscal quarter
Q3 FY26

EPSReportedEstimate

Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$0.54−$0.42−$0.40−$0.39−$0.36−$0.30−$0.57Pending
Estimate−$0.51−$0.49−$0.53−$0.46−$0.46−$0.36−$0.38−$0.35
Surprise−5.9%+14.3%+24.5%+15.2%+21.7%+16.7%−50.0%

RevenueReportedEstimate

Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$100.7KPending
Estimate
Surprise

History

DateEstimateReportedSurprise
Nov 2026−$0.35
Aug 2026−$0.38−$0.57−50.0%
May 2026−$0.36−$0.30+16.7%
Mar 2026−$0.46−$0.36+21.7%
Nov 2025−$0.46−$0.39+15.2%

The latest year is open to everyone — the 26 quarters behind it read with an account.

Sign in
Aug 2025
May 2025
Mar 2025
Nov 2024
Aug 2024
May 2024
Mar 2024
Nov 2023
Aug 2023
May 2023
Mar 2023
Nov 2022
Aug 2022
May 2022
Mar 2022
Nov 2021
Jul 2021
May 2021
Mar 2021
Oct 2020
Jul 2020
Jun 2020
Dec 2019
Sep 2019
Jun 2019
Mar 2019
Report dateEPS estEPSSurpriseRevenue estRevenueSurpriseReaction
Nov 11, 2026−$0.35
Aug 14, 2026−$0.38−$0.57−50.0%+0.8%
May 15, 2026−$0.36−$0.30+16.7%−4.5%
Mar 30, 2026−$0.46−$0.36+21.7%+10.5%
Nov 12, 2025−$0.46−$0.39+15.2%−0.6%

The latest year is open to everyone — the 26 quarters behind it read with an account.

Sign in
Aug 13, 2025
May 15, 2025
Mar 27, 2025
Nov 7, 2024
Aug 8, 2024
May 9, 2024
Mar 18, 2024
Nov 8, 2023
Aug 9, 2023
May 9, 2023
Mar 20, 2023
Nov 7, 2022
Aug 8, 2022
May 3, 2022
Mar 10, 2022
Nov 1, 2021
Jul 29, 2021
May 3, 2021
Mar 10, 2021
Oct 29, 2020
Jul 30, 2020
Jun 12, 2020
Dec 31, 2019
Sep 30, 2019
Jun 30, 2019
Mar 31, 2019